RSS Alerts
  • Home
  • /
  • News
  • /
  • Biotherapeutics
  • /
  • July 2009

Biotherapeutics News for July 2009

Biotherapeutics News Archive

Debiopharm and MSM Protein Technologies sign agreement for research and development of Debio 0929, a novel oncology biologic Debiopharm and MSM Protein Technologies sign agreement for research and development of Debio 0929, a novel oncology biologic

Debiopharm Group and MSM Protein Technologies have announced the signature of an exclusive agreement for the development and commercialization of Debio 0929, an antibody targeting a G-protein-coupled receptor (GPCR) to be developed into a new oncology therapeutic drug.

Ilaris® recommended for European approval as new biologic drug to treat a rare group of auto-inflammatory diseases Ilaris® recommended for European approval as new biologic drug to treat a rare group of auto-inflammatory diseases

The biotechnology medicine Ilaris® (canakinumab) has been recommended for approval in the European Union to treat patients with the life-long and potentially fatal auto-inflammatory disease cryopyrin-associated periodic syndrome.

Ablynx announces a novel preclinical development candidate targeting the interleukin-6 receptor Ablynx announces a novel preclinical development candidate targeting the interleukin-6 receptor

Ablynx, a biopharmaceutical company focused on the discovery and development of Nanobodies, has announced recently that it has advanced ALX-0061, a new Nanobody-based therapeutic programme, into preclinical development for the treatment of autoimmune and inflammatory diseases.

Copyright © 2024
Elsevier Ltd. All rights reserved.
Sitemap | Terms & Conditions | Privacy | | Website Design Working with water